Trial Profile

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Alectinib; Bevacizumab; Cabozantinib; Cobimetinib; Emactuzumab; Enzalutamide; Erlotinib; Niraparib; Paclitaxel; Pembrolizumab; Pemetrexed; Rucaparib; Simlukafusp alfa; Sunitinib; Vemurafenib; Venetoclax
Indications Advanced breast cancer; Cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Male breast cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
Focus Registrational; Therapeutic Use
Acronyms IMbrella B
Sponsors Chugai Pharmaceutical; Roche

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com